Αναπαραγωγή και κύηση στις ιδιοπαθείς φλεγμονώδεις...
of 42
-
Upload
theo2501 -
Category
Health & Medicine
-
view
220 -
download
6
Transcript of Αναπαραγωγή και κύηση στις ιδιοπαθείς φλεγμονώδεις...
- 1. , MD American Medical Center 23/5/2015
- 2. () : Crohn . . Crohn . , .
- 3. ( 15 30 ) .
- 4. Crohn . , Crohn . Crohn : - - - . - (IPAA) . IPAA , IPAA.
- 5. . ( ) .
- 6. ? . ( 33%). .
- 7. () - . . .
- 8. ? Crohns . .
- 9. ? . Crohn. 2-13 . . , 30%. Crohn, . .
- 10. ? . - , - . .
- 11.
- 12. / . . !!! .
- 13. (( )). , . () . .
- 14. () 6- (6-) AZA 6- . meta-analysis , . . .
- 15. tacrolimus , - 15 410 . . , tacrolimus.
- 16. () . , . 3-6 ( ). , , ' . .
- 17. (Anti-TNF) infliximab(Remicade) Adalimumab(Humira) IgG 1 , . infliximab . Adalimumab, . . infliximab Adalimumab . ( 24 ) .
- 18. (Anti-TNF) Certolizumab pegol (Cimzia) infliximab Adalimumab. . .
- 19. . , .
- 20. .
- 21. / . . , 4 . , . .
- 22. . . infliximab Adalimumab . . .
- 23.
- 24. nfliximab(Remicade) IgG1 - TNF-. 2/3 Crohn infliximab , 1/3 . Crohn . Infliximab , , (pouchitis), , . .
- 25. Adalimumab(Humira) IgG1 TNF-. Crohn . / , . -TNF.
- 26. Golimumab (Simponi) -TNFa. , . .
- 27. : golimumab , , .
- 28. : Golimumab (50 mg 100 mg) 54 . TNFa golimumab .
- 29. Ustekinumab (Stelara) IgG1, -12 -23. . Crohn, TNF.
- 30. Crohn, TNF ustekinumab, . ustekinumab ustekinumab .
- 31. Vedolizumab (Entyvio) IgG 1 4 7 . Crohn , (TNF-) . , (TNF-) .
- 32. 9 (CCR9) Traficet-EN Crohn. CCR9 Traficet-EN - . IIb Crohn, Traficet-EN 12 , 36 .
- 33. Tofacitinib, Janus. 2 Crohn. .
- 34. Mongersen , SMAD7, TGF-. 1 Crohn 2012 .
- 35. -, , 2. ( 18 75 ), Crohn, . Crohn mongersen .
- 36. Inflectra ( Remicade) , . , , . -TNF . , .
- 37. Poster presentations: Clinical: Therapy & observation (2015) P505 Biosimilar but not the same C. Murphy*, K. Sugrue, G. Mohamad, J. McCarthy, M. Buckley Mercy University Hospital, University College Cork, Centre for Gastroenterology, Mercy University Hospital, Cork, Ireland 14 Inflectra Remicade , , , CRP. : Inflectra .
- 38. Poster presentations: Clinical: Therapy & observation (2015) P314 Biosimilar infliximab in inflammatory bowel diseases: first interim Results from a prospective nationwide observational cohort K. Gecse*1, K. Farkas2, B. Lovasz1, J. Banai3, L. Bene4, B. Gasztonyi5, P.A. Golovics1, T. Kristof6, L. Lakatos7, P. Miheller8, F. Nagy9, K. Palatka10, M. Papp10, A. Patai11, A. Salamon12, T. Szamosi3, Z. Szepes9, G.T. Toth13, A. Vincze14, T. Molnar2, P. Lakatos1 90 Inflectra. CRP . .
- 39.
